SalaryGuide
AboutPricingFor Employers

Marketing jobs

1 marketing jobs

Cytokinetics logo
3 days ago

Director, US Patient Marketing

Cytokinetics

South San Francisco, CA (Hybrid)Full time$225K/yr – $263K/yr

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

1 jobs
Cytokinetics logo

Director, US Patient Marketing

Cytokinetics

South San Francisco, CA (Hybrid)

$225K/yr - $263K/yrIn-houseFull-timeDirector/executive10+ years exp.
3 days ago
Cytokinetics logo
Cytokinetics

Director, US Patient Marketing

South San Francisco, CA (Hybrid)

$225K/yr – $263K/yrDirector/Executive10+ years expFull time

Posted 3 days ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Own the end-to-end patient media strategy and performance, turning data and insights into clear recommendations for brand investments and cross-channel optimization.

  • Define audience strategies and unified measurement linking digital engagement to patient outcomes
  • Lead KPI design, dashboards, and performance reporting for media and patient outcomes
  • Lead testing, optimization, and adoption of emerging marketing technologies with IT and analytics partners

Job Description

Responsibilities

  • Own end-to-end patient media strategy to ensure consistent reach, frequency, and storytelling across platforms.
  • Manage all media planning, buying, optimization, performance measurement, including audience targeting, as well as associated budget.
  • Define audience strategies using claims-based data, behavioral insights, contextual targeting, and first-party data.
  • Own all marketing and media metrics, measurement frameworks, and performance optimization
  • Lead design and governance of KPIs across media, ensuring consistent definitions and reporting standards.
  • Develop and maintain a unified measurement framework connecting digital engagement to patient outcomes.
  • Own dashboards and performance reporting for patient.
  • Partner with Commercial Analytics and Data Science teams to integrate media, CRM, web, and claims-based data.
  • Develop and lead testing frameworks
  • Translate complex data into clear, actionable recommendations for brand strategy and investment decisions.

Requirements

  • Minimum 4+ years of U.S. pharmaceutical brand marketing experience.
  • Minimum 2+ years of experience managing/leading pharmaceutical patient media
  • Bachelor’s degree in Marketing, Business, Analytics, Statistics, Communications, or related field.
  • 10+ years of experience in pharmaceutical, biotechnology, or healthcare marketing.
  • Mature metrics governance and performance measurement framework.
  • 2+ years of hands-on patient media experience in a pharmaceutical or healthcare setting.
  • Strong background in media analytics, attribution, testing, and performance optimization.
  • Experience working in highly regulated industries with MLR review processes.
  • Strong alignment between media investment and patient engagement outcomes.
  • Strong communication and stakeholder management skills.

Preferred

  • MBA or advanced degree.
  • Experience launching or supporting specialty, cardiovascular, or complex pharmaceutical brands.
  • Experience building omnichannel measurement frameworks
  • Experience working with IT/data engineering teams on marketing technology infrastructure.
  • Experience in black box, REMs, rare disease and/or specialty pharma is a plus.

Benefits

  • comprehensive health, dental, vision, life and disability insurance coverage, 401k retirement benefits with employer match, learning and wellness stipends, and paid time off.
Cytokinetics logo

Cytokinetics

3.3 Glassdoor

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, we are developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Proud to be a San Francisco Business Times Best Place to Work in 2021 and 2022, a Great Place to Work-Certified company in 2022 and a part of Fortune's Best Workplaces in the Bay Area in 2022 and Fortune's Best Workplaces in BioPharma in 2022.

Founded in 1998
South San Francisco, California, USA
726 employees (36 in marketing)
www.cytokinetics.com
48% recommend to a friend
83% CEO approval

Traffic Signals

Monthly Visitors
14.4K
Traffic Source Mix
Search
51.1%
Direct
40.2%
Referral
5.6%
Social
1.2%
Paid
1.7%

Headcount Trend

Current headcount: ~727

Marketing Team

Marketing Team Size
36 (5% of company)
Median Tenure
2.3 years
Marketing Roles Posted (Last 30 Days)
1

Funding

Total Funding
$2.4B
Last Raise
$650M
Post IPO Debt, 6 months ago

Funding History

  • Sep 2025
    Post IPO Debt • $650M
  • May 2024
    Post IPO Debt • $50M
  • May 2024
    Post IPO Equity • $550M

Recent News

Why Is Cytokinetics (CYTK) Up 10.4% Since Last Earnings Report?
Dec 5, 2025 • Yahoo Finance
Cytokinetics: Approval Catalyst In December - But Risk Reward Is Not Compelling (CYTK)
Nov 21, 2025 • Seeking Alpha
Cytokinetics (CYTK): Assessing Valuation After Fresh Legal Scrutiny and New Risks to FDA Timeline
Nov 20, 2025 • simplywall.st
Cytokinetics: A Heavily Mispriced Cardiovascular Platform (NASDAQ:CYTK)
Nov 19, 2025 • Seeking Alpha
'We're built for it': Why Cytokinetics doesn't want Big Pharma support to help it supersede Camzyos
Nov 18, 2025 • Fierce Biotech
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Nov 18, 2025 • Yahoo Finance
Cytokinetics Supports American Heart Association Initiative to Improve Care for People Living With Hypertrophic Cardiomyopathy
Nov 17, 2025 • Yahoo Finance
CYTK Investors Have Opportunity to Lead Cytokinetics, Incorporated Securities Fraud Lawsuit with the Schall Law Firm
Nov 17, 2025 • GlobeNewswire
Cytokinetics joins Bristol Myers in funding heart registry ahead of commercial clash
Nov 17, 2025 • Fierce Pharma
Cytokinetics appoints Jeffrey J. Hessekiel as EVP and chief legal officer
Nov 14, 2025 • Investing.com
Cytokinetics (CYTK) Is Up 8.7% After Strong Aficamten Data and FDA Delay Disclosures – Has the Bull Case Changed?
Nov 14, 2025 • Yahoo Finance
Cytokinetics Gains 11.4% in a Week: Is There More Room for Growth?
Nov 13, 2025 • Yahoo Finance
Cytokinetics at Stifel 2025 Healthcare Conference: Strategic Insights on Aficamten
Nov 11, 2025 • Investing.com
B. Riley Adjusts Price Target on Cytokinetics to $90 From $80, Maintains Buy Rating
Nov 10, 2025 • MarketScreener
Cytokinetics Presents Additional Data from MAPLE-HCM at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025
Nov 10, 2025 • MarketScreener
Cytokinetics Presents Additional Data from MAPLE-HCM at the
Nov 10, 2025 • GlobeNewswire
Cytokinetics Presents Additional Data from MAPLE-HCM at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025
Nov 10, 2025 • Yahoo Finance
Cytokinetics (NASDAQ: CYTK) reports 73% NT-proBNP drop with aficamten vs 42% rise
Nov 10, 2025 • Stock Titan
HC Wainwright Decreases Earnings Estimates for Cytokinetics
Nov 10, 2025 • Defense World
Cytokinetics outlines aficamten U.S. and EU launch plans with $1.2B in cash as FDA decision nears
Nov 9, 2025 • MSN
Cytokinetics Shareholder Alert By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Cytokinetics, Incorporated - CYTK
Nov 8, 2025 • PR Newswire
Cytokinetics (CYTK) Faces Class Action Over Misleading Aficamten Claims
Nov 7, 2025 • TipRanks
Why Analysts Say the Cytokinetics Story Is Evolving Amid Key Aficamten Milestones
Nov 7, 2025 • Yahoo Finance
Cytokinetics’ Earnings Call: Progress and Challenges
Nov 7, 2025 • TipRanks
Cytokinetics (CYTK) Advances Toward FDA Approval with Strong Q3 Results
Nov 6, 2025 • GuruFocus
Cytokinetics: Q3 Earnings Snapshot
Nov 6, 2025 • CT Insider
Decoding Cytokinetics Inc (CYTK): A Strategic SWOT Insight
Nov 6, 2025 • GuruFocus
Cytokinetics (CYTK) Q3 2025 Earnings Transcript
Nov 6, 2025 • The Motley Fool
Will Cytokinetics Incorporated stock keep outperforming rivals - Earnings Miss & Risk Managed Investment Strategies
Nov 6, 2025 • Fundação Cultural do Pará
Cytokinetics Banks On FDA Decision For Its Heart Drug
Nov 5, 2025 • Finimize
Cytokinetics Inc earnings missed by $0.98, revenue fell short of estimates
Nov 5, 2025 • Investing.com
Cytokinetics (CYTK) Reports Q3 Loss, Lags Revenue Estimates
Nov 5, 2025 • Yahoo Finance
Cytokinetics Reports Third Quarter 2025 Financial Results and Provides Business Update
Nov 5, 2025 • Yahoo Finance
Cytokinetics (NASDAQ: CYTK) aficamten PDUFA set for Dec 26, 2025 as launch prep advances
Nov 5, 2025 • Stock Titan
Investors SueWallSt as Cytokinetics, Incorporated Faces Securities Fraud Allegations
Nov 5, 2025 • Nasdaq
Earnings call transcript: Cytokinetics Q3 2025 reveals revenue miss, stock steady
Nov 5, 2025 • Investing.com
Cytokinetics Inc (CYTK) Q3 2025 Earnings Call Highlights: Progress Towards Aficamptin Approval ...
Nov 5, 2025 • Yahoo Finance
Cytokinetics (NASDAQ: CYTK) to join Stifel, Jefferies Nov 11 & Nov 17; live webcasts
Nov 4, 2025 • Stock Titan
Cytokinetics to Participate in November Investor Conferences
Nov 4, 2025 • Yahoo Finance
Cytokinetics Inc (CYTK) Q3 2025 Earnings Report Preview: What To Expect
Nov 4, 2025 • GuruFocus
Portnoy Law Firm Announces Class Action on Behalf of Cytokinetics, Incorporated Investors
Nov 4, 2025 • GlobeNewswire
Cytokinetics Inc (CYTK) Q3 2025 Earnings Report Preview: What To Expect
Nov 4, 2025 • Yahoo Finance
Cytokinetics to Participate in November Investor Conferences
Nov 4, 2025 • GlobeNewswire
CYTOKINETICS CLASS ACTION: Bragar Eagel & Squire, P.C.
Nov 3, 2025 • GlobeNewswire
Cytokinetics Announces Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025
Oct 31, 2025 • Yahoo Finance
Cytokinetics (NASDAQ: CYTK) to present at HCMS and AHA 2025; 3 MAPLE-HCM Late-Breaking
Oct 31, 2025 • Stock Titan
Cytokinetics Announces Upcoming Late Breaking Science Presentations on Aficamten at Major Cardiovascular Conferences
Oct 31, 2025 • Quiver Quantitative
Investors SueWallSt as Cytokinetics, Incorporated Faces Securities Fraud Allegations
Oct 30, 2025 • Nasdaq
Cytokinetics (CYTK): Exploring Valuation After Recent Share Price Momentum and Growth Narrative
Oct 30, 2025 • Yahoo Finance
Cytokinetics Shareholder Alert: ClaimsFiler Reminds
Oct 29, 2025 • GlobeNewswire
Cytokinetics has been on a tear as the biotech pioneers more drugs to fight heart ailments
Oct 28, 2025 • CNBC
How buybacks impact Cytokinetics Incorporated stock value - Market Risk Report & AI Forecast for Swing Trade Picks
Oct 27, 2025 • Fundação Cultural do Pará
Key facts: Cytokinetics shares fall 12.98% after FDA decision; lawsuit filed
Oct 25, 2025 • TradingView
Deadline Alert: Cytokinetics, Incorporated (CYTK)
Oct 23, 2025 • GlobeNewswire
Cytokinetics (Nasdaq: CYTK) schedules results for 4:00 PM ET; call at 4:30 PM
Oct 22, 2025 • Stock Titan
Insider Sell Alert: Fady Malik Sells Shares of Cytokinetics Inc (CYTK)
Oct 21, 2025 • GuruFocus
Malik, Cytokinetics EVP, sells $122k in CYTK stock
Oct 21, 2025 • Investing.com
Levi & Korsinsky Reminds Cytokinetics, Incorporated Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 17, 2025 - CYTK
Oct 21, 2025 • Sahm
Top Executive Sells Thousands of Cytokinetics Shares!
Oct 21, 2025 • TipRanks
Cytokinetics, Incorporated (CYTK) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Oct 21, 2025 • PR Newswire
Deadline Alert: Cytokinetics, Incorporated (CYTK)
Oct 16, 2025 • GlobeNewswire
Cytokinetics (CYTK) CEO Blum sells $300k in shares
Oct 16, 2025 • Investing.com
Class Action Filed Against Cytokinetics, Incorporated (CYTK) - November 17, 2025 Deadline to Join – Contact The Gross Law Firm
Oct 16, 2025 • GlobeNewswire
Cytokinetics stock hits 52-week high at 61.48 USD
Oct 14, 2025 • Investing.com
Cytokinetics Shareholder Alert By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Cytokinetics, Incorporated - CYTK
Oct 11, 2025 • PR Newswire
Investors who lost money on Cytokinetics, Incorporated(CYTK) should contact Levi & Korsinsky about pending Class Action - CYTK
Oct 10, 2025 • PR Newswire
Investors who lost money on Cytokinetics, Incorporated(CYTK) should contact Levi & Korsinsky about pending Class Action - CYTK
Oct 10, 2025 • Morningstar
Portnoy Law Firm Announces Class Action on Behalf of Cytokinetics, Incorporated. Investors
Oct 9, 2025 • GlobeNewswire
Deadline Alert: Cytokinetics, Incorporated (CYTK) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Oct 9, 2025 • GlobeNewswire
Cytokinetics, Incorporated Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before November 17, 2025 to Discuss Your Rights - CYTK
Oct 9, 2025 • PR Newswire
Have Insiders Sold Cytokinetics Shares Recently?
Oct 9, 2025 • simplywall.st
Cytokinetics’ SWOT analysis: aficamten’s potential reshapes HCM treatment landscape
Oct 8, 2025 • Investing.com
Top Executive Sells Thousands in Cytokinetics Stock!
Oct 8, 2025 • TipRanks
December 19th Options Now Available For Cytokinetics (CYTK)
Oct 7, 2025 • Nasdaq
Cytokinetics Director Makes a Significant Stock Sale!
Oct 7, 2025 • TipRanks
Robbins LLP Reminds Cytokinetics, Inc. Investors of the Upcoming Lead Plaintiff Deadline in the Class Action Against CYTK
Oct 6, 2025 • PR Newswire
CYTK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Cytokinetics, Incorporated Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit | FinancialContent
Oct 6, 2025 • FinancialContent
Cytokinetics stock hits 52-week high at 59.5 USD
Oct 6, 2025 • Investing.com
Cytokinetics stock price target raised to $82 from $71 at Barclays
Oct 6, 2025 • Investing.com
ROSEN, A LEADING AND RANKED FIRM, Encourages Cytokinetics,
Oct 4, 2025 • GlobeNewswire
Cytokinetics, Incorporated (NASDAQ:CYTK) Given Average Rating of “Moderate Buy” by Brokerages
Oct 4, 2025 • Defense World
Portnoy Law Firm Announces Class Action on Behalf of Cytokinetics, Inc. Investors
Oct 3, 2025 • GlobeNewswire
Can CYTK Clinch a Potential FDA Nod for Its Cardiovascular Drug?
Oct 2, 2025 • Yahoo Finance
Stifel lowers Cytokinetics stock price target to $95 on recent convert deal
Oct 1, 2025 • Investing.com
Shareholders SueWallSt in New Class Action Against Cytokinetics, Incorporated - Act Now
Sep 30, 2025 • Nasdaq
Cytokinetics at Stifel Forum: Strategic Insights on Aficamten
Sep 30, 2025 • Investing.com
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics
Sep 30, 2025 • GlobeNewswire
Cytokinetics stock maintains Buy rating as H.C. Wainwright cites exercise data
Sep 30, 2025 • Investing.com
CYTOKINETICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY
Sep 30, 2025 • GlobeNewswire
Cytokinetics, Incorporated Securities Lawsuit Investigation
Sep 29, 2025 • Claim Depot
Class Action Filed Against Cytokinetics, Incorporated (CYTK) Seeking Recovery for Investors - Contact The Gross Law Firm
Sep 29, 2025 • PR Newswire
Cytokinetics Presents New Data Related To Aficamten
Sep 29, 2025 • TradingView
Cytokinetics stock maintains Buy rating at Stifel on promising aficamten data
Sep 29, 2025 • Investing.com
82% Success Rate: Cytokinetics' Heart Drug Aficamten Outperforms Standard Treatment in Key Measures
Sep 29, 2025 • Stock Titan
HC Wainwright & Co. Reiterates Cytokinetics (CYTK) Buy Recommendation
Sep 29, 2025 • Nasdaq
Cytokinetics Presents New Data Related to Aficamten at the HFSA Annual Scientific Meeting 2025
Sep 29, 2025 • Yahoo Finance
Cytokinetics Stock Scores RS Rating Jump To 83
Sep 29, 2025 • Investor's Business Daily
CYTK Investors Have Opportunity to Lead Cytokinetics, Inc. Securities Fraud Lawsuit
Sep 24, 2025 • Morningstar
Important Notice to Long-Term Shareholders of Cytokinetics,
Sep 23, 2025 • GlobeNewswire
Cytokinetics to Present at the Stifel 2025 Virtual Cardiometabolic Forum
Sep 23, 2025 • Yahoo Finance